Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.62 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.62 |
| ▸ | ACE | P12821 | 6/20 | 0.60 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.60 |
| ▸ | MME | P08473 | 1/20 | 0.60 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.57 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | CDC25B | P30305 | 1/20 | 0.56 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4147924 | 1.00 | ITGB3 (0.62) | ITGB3ITGA2BACEGRIA1MME | |
| SCHEMBL4147413 | 1.00 | ITGB3 (0.62) | ITGB3ITGA2BACEGRIA1MME | |
| SCHEMBL4147417 | 1.00 | ITGB3 (0.62) | ITGB3ITGA2BACEGRIA1MME | |
| SCHEMBL4147882 | 0.96 | NAALAD2 (0.61) | ITGB3ITGA2BACEGRIA1MME | |
| SCHEMBL4147877 | 0.96 | NAALAD2 (0.61) | ITGB3ITGA2BACEGRIA1MME | |
| SCHEMBL5458748 | 0.93 | ITGB3 (0.65) | ITGB3ITGA2BACEMMENAALAD2 | |
| SCHEMBL4153095 | 0.93 | ITGB3 (0.65) | ITGB3ITGA2BACEMMENAALAD2 | |
| SCHEMBL4153101 | 0.93 | ITGB3 (0.65) | ITGB3ITGA2BACEMMENAALAD2 | |
| SCHEMBL30845347 | 0.89 | NAALAD2 (0.54) | ITGB3ITGA2BACEGRIA1MME | |
| SCHEMBL30081065 | 0.89 | ACE (0.56) | ITGB3ITGA2BACEGRIA1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111874-A1 | Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU PHARMENTERPRISES (RU) | 2009-04-30 | — | — | US | claimed |
| EP-1876169-A1 | PHENYL-CONTAINING N-ACYL AMINE AND AMINOACID DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, A PHARMACEUTICAL COMPOSITION AND THE USE THEREOF | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2008-01-09 | — | — | EP | claimed |
| CN-118272840-A | Method for electrochemical synthesis of thiocarbamate-labeled tyrosine-containing biomolecules | 广西师范大学 | 2024-07-02 | — | — | CN | disclosed |
| CN-116546988-A | Prodrugs of 5α -hydroxy-6β - [2- (1H-imidazol-4-yl) ethylamino ] cholestan-3β -ol and pharmaceutical compositions for cancer treatment containing the same | 登德罗杰尼克斯公司 | 2023-08-04 | — | — | CN | disclosed |
| EP-1876169-B1 | PHENYL-CONTAINING N-ACYL AMINE AND AMINOACID DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, A PHARMACEUTICAL COMPOSITION AND THE USE THEREOF | OBSCHESTVO S OGRANICHENNOI OTVETSTENNOSTIYU PHARMENTPR (RU) | 2015-12-30 | — | — | EP | disclosed |
| CN-101180267-B | Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof | OBSCHESTVO S OGRANICHENNOI OTV | 2015-06-17 | — | — | CN | disclosed |
| US-8546612-B2 | Phenyl-N-acyl derivatives of amines and amino acids, a process for the preparation thereof, a pharmaceutical composition and use thereof | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU PHARMENTERPRISES (RU) | 2013-10-01 | — | — | US | disclosed |
| US-20130109880-A1 | PHENYL-N-ACYL DERIVATIVES OF AMINES AND AMINO ACIDS, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL COMPOSITION AND USE THEREOF | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU PHARMENTERPRISES (RU) | 2013-05-02 | — | — | US | disclosed |
| US-8309766-B2 | Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof | Obschestvo S. Organichennoi Otvetstvennostiyu Pharmenterprises (RU) | 2012-11-13 | — | — | US | disclosed |
| US-20090111874-A1 | Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU PHARMENTERPRISES (RU) | 2009-04-30 | — | — | US | disclosed |
| CN-101180267-A | Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof | OBSCHESTVO S OGRANICHENNOI OTV (RU) | 2008-05-14 | — | — | CN | disclosed |
| EP-1876169-A1 | PHENYL-CONTAINING N-ACYL AMINE AND AMINOACID DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, A PHARMACEUTICAL COMPOSITION AND THE USE THEREOF | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2008-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109880-A1 | PHENYL-N-ACYL DERIVATIVES OF AMINES AND AMINO ACIDS, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL COMPOSITION AND USE THEREOF | MAOA, PAH, MAOB | ITGB3 4238/4885ITGA2B 3436/4885ACE 453/4885 |
| US-20090111874-A1 | Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof | PAH, MAOA, APEH | ITGB3 4262/4885ITGA2B 3589/4885ACE 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.